BioGend Therapeutics Co., Ltd.

NT$21.00As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6733Healthcare
Country Taiwan
PE (Fwd) •••
TSR 7Y CAGR (5.35%)
Div yield —
ROE (9.91%)
Biotechnology
Beta (5Y) 0.13
PE TTM —
TSR TTM (52.45%)
Mkt cap NT$2.821B
ROIC (7.34%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$26
23.06%
(81.13%)
Hold 10|0|10|8|9
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.25
0.27
0.29
0.28
19.22%
23.59%
23.12%
19.40%
RevenueNT$M
118.6
116.1
116.8
119.5
1.17%
1.00%
(0.90%)
(0.53%)
Peers (US$85.19M)
Cap (US$)
PE
88.97M
—
85.32M
22.67x
Capital
TTM
5Y
10Y
Leveragex
0.512
0.055
0.046
EBIT/Intx
1.130
0.292
0.346
Own earn%
(0.14)
(29.41)
(40.01)
Sh yield%
26.69
44.54
41.96
Owners
Insiders/Inst%
0.99
38.24
Short interest%
3.93
SBC / revenue%
1.02
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
4–7
$1 testx
0.0
Incr. ROIC%
4